Robert Hadden, BM BCh, FRCP, PhD, King’s College Hospital, London, UK, discusses the predictive markers of patients likely to experience neurotoxicity symptoms, and how such symptoms may arise. This interview took place at the CAR-T Cell Therapy and the ICU meeting in London, UK, which was organized by EuroCARTForce.